Abbott Laboratories (NYSE:ABT) has been downgraded to Hold in a report by Zacks Investment Research earlier today.
- Updated: October 4, 2016
Yesterday Abbott Laboratories (NYSE:ABT) traded -1.08% lower at $41.94. ABT’s 50-day average is $42.51 and its two hundred day average is $41.32. With the last stock price up 1.86% relative to the 200-day moving average, compared to the Standard & Poor's 500 Index which has decreased -0.01% over the same time. 4,704,072 shares of Abbott Laboratories exchanged hands, down from an avg. volume of 9,484,880
Zacks Investment Research has downgraded Abbott Laboratories (NYSE:ABT) to Hold in a report released on 10/04/2016.
Previously on 9/20/2016, Zacks Investment Research released a statement for Abbott Laboratories (NYSE:ABT) raised the target price from $0.00 to $47.00 that indicated a possible upside of 0.12%.
Recent Performance Chart
Abbott Laboratories has a 52 week low of $36.00 and a 52 week high of $46.38 with a P/E ratio of 27.78 ABT’s total market value is presently $0.
A total of 15 equity analysts have released a ratings update on the stock. Six analysts rating the company a strong buy, 8 brokerages rating the company a buy, six brokers rating the stock a hold, 0 brokers rating the stock a underperform, and finally 0 firms rating the stock a sell with a consensus price target of $46.73.
General Company Details For Abbott Laboratories (NYSE:ABT)
Abbott Laboratories (Abbott) is engaged in the discovery, development, manufacture and sale of a line of healthcare products. The Company operates in four business segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products and Vascular Products. The Established Pharmaceutical Products segment includes the international sales of a line of branded generic pharmaceutical products. The Diagnostic Products segment includes the sales of a line of adult and pediatric nutritional products. The Nutritional Products includes the sales of diagnostic systems and tests for blood banks, commercial laboratories and alternate-care testing sites. The Vascular Products includes the sales of coronary, endovascular, structural heart, vessel closure and other medical device products. Its Established Pharmaceutical Products segment's therapeutic area portfolio of products includes gastroenterology products, women's health products, and respiratory drugs and vaccines.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.